COMMUNIQUÉS West-GlobeNewswire

Microbot Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform
14/12/2017
HINGHAM, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT ), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today [...]
Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
14/12/2017
Builds on preclinical research conducted at Duke University and clinical research conducted by Axsome Smoking cessation is the third indication for AXS-05 Phase 2 trial initiation anticipated in the first quarter of [...]
HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
14/12/2017
WATERTOWN, Mass. and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug delivery products, and Hospital for Special Surgery (HSS), [...]
Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)
14/12/2017
CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
14/12/2017
IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important cardiac research [...]
Kraig Biocraft Laboratories Begins Operations in New Laboratory
14/12/2017
ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has completed the build [...]
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
14/12/2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
14/12/2017
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]
Norrlandsfonden begär konvertering av utestående konvertibellån
14/12/2017
C-RAD har under perioden 2006 – 2013 ställt ut konvertibla skuldebrev till Norrlandsfonden. Samtliga skuldebrev har en löptid t o m 31 januari 2018 om inte konvertering dessförinnan påkallats av konvertibelägare. C-RAD [...]
Issuance of shares pursuant to the restricted share unit reward plan
14/12/2017
Company announcement, Helsinki, 14 December 2017, at 9 am Issuance of shares pursuant to the restricted share unit reward plan Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), a medical technology [...]
Proteostasis Therapeutics Prices Public Offering of Common Stock
14/12/2017
CAMBRIDGE, Mass., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI ), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to [...]
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering
14/12/2017
Regulated information - Inside information Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody- [...]
Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration
13/12/2017
MELBOURNE, Australia and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“ Telix ”, the “ Company ”), an Australian biopharmaceutical company focused on the development of diagnostic [...]
DiaMedica Therapeutics Announces Non-Brokered Private Placement
13/12/2017
MINNEAPOLIS, Dec. 13, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “ Company ”) (TSX-V: DMA ) (OTCQB:DMCAF), announces that, subject to TSX Venture Exchange approval, it is undertaking a non-brokered [...]
Nabriva Therapeutics Added to NASDAQ Biotechnology Index
13/12/2017
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV ), a clinical stage biopharmaceutical company engaged in the research and development of novel anti- [...]
Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee
13/12/2017
Acquisition complements existing portfolio with an innovative, locally administered therapeutic intended to provide persistent effective concentrations of IL-1Ra in the knee for at least a year New preclinical program [...]
ExactCare Pharmacy Welcomes Terry Rogers as Chief Growth Officer
13/12/2017
CLEVELAND, Dec. 13, 2017 (GLOBE NEWSWIRE) -- ExactCare® Pharmacy has expanded its Executive Leadership Team, welcoming seasoned health care executive Terry Rogers to the newly created role of Chief Growth Officer (CGO [...]
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017
13/12/2017
EDISON, N.J., Dec. 13, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today [...]
AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
13/12/2017
– The FDA notified AveXis it may initiate the Phase 1 trial in SMA Type 2 based on a review of data provided by the company; trial to commence immediately – – The trial will evaluate safety, dosing and proof of concept [...]

Pages